Kite Pharma, Inc. (NASDAQ:KITE) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On February28, 2017, Kite Pharma, Inc. (Kite) provided a
corporate update and announced its financial results for the
fourth quarter ended December31, 2016 and its full-year financial
results for the year ended December31, 2016 in the press release
attached hereto as Exhibit 99.1 and incorporated herein by
reference.
The information in this Item2.02, including the attached Exhibit
99.1, is being furnished and shall not be deemed filed for the
purposes of Section18 of the Securities Exchange Act of 1934 (the
Exchange Act), or otherwise subject to the liabilities of that
Section, nor shall it be deemed incorporated by reference in any
filing made by Kite under the Securities Act of 1933 or the
Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
| Item9.01 | Financial Statements and Exhibits. |
(d)Exhibits.
The following exhibit is filed as part of this Current Report:
| 99.1 | Press Release of Kite, dated February28, 2017. |
About Kite Pharma, Inc. (NASDAQ:KITE)
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy. It is conducting a Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with refractory diffuse large B cell lymphoma (DLBCL), including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is also conducting a Phase II clinical trial (ZUMA-2) of KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL), a Phase I-II clinical trial (ZUMA-3) of KTE-C19 in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), and a Phase I-II clinical trial (ZUMA-4) of KTE-C19 in pediatric patients with relapsed/refractory ALL. Kite Pharma, Inc. (NASDAQ:KITE) Recent Trading Information
Kite Pharma, Inc. (NASDAQ:KITE) closed its last trading session 00.00 at 56.83 with 1,191,223 shares trading hands.